Erythropoietin (Epo) binding to its receptor (EpoR) induces tyrosine phosphorylation in responsive cells and this ability is required for a mitogenic response. One of the substrates of tyrosine phosphorylation is the Epo receptor (EpoRI. The carboxyl region of EpoR cytoplasmic domain is required for EpoR phosphorylation and has been shown to negatively affect the response to Epo both in vivo and in cell lines. Hematopoietic cell phosphatase (HCP) has also been hypothesized to negatively regulate erythropoiesis, based on the hypersensitivity to Epo of erythroid lineage cells in motheaten mice that genetically lack HCP.
RYTHROPOIESIS is regulated through the interaction of erythropoietin (Epo) with its receptor (EpoR), a member of the cytokine receptor superfamily of receptors.'-4 A variety of studies support the hypothesis that EpoR functions to control growth and support differentiation by coupling ligand binding to the induction of tyrosine phosphorylation. In particular, Epo rapidly induces tyrosine phosphorylation and this ability correlates with a mitogenic response among a variety of receptor
The EpoR, which lacks intrinsic kinase activity, couples ligand binding to phosphorylation by association with the cytoplasmic protein tyrosine kinase Janus kinase 2 (Jak2).7,8 After activation of Jak2, a number of cellular proteins are tyrosine phosphorylated including GTPase activating protein (GAP): SHC," and the receptor i t~e l f .~. "~'~
The phosphorylated tyrosine residues on the EpoR are docking sites for proteins containing src homology 2 (SH2) domains including SHC" and the p85 regulatory subunit of phosphatidylinositol 3-kinase (PI-3-k i n a~e ) . '~"~ The cytoplasmic portion of EpoR consists of two functional domains." The membrane proximal region contains the conserved box-l and box-2 motifs that are found in a number of cytokine receptors.18 This region is required and sufficient for mitogenesis and for coupling ligand binding to the induction of tyrosine phosphorylati~n.~*~'~ The membrane proximal region is also required and sufficient for the association of Jak2 with E~oR.~.' In contrast, the membrane distal region of the cytoplasmic domain is either not required for receptor function or negatively influences the response of cells to Epo.I7 Indeed, truncation of the carboxyl terminal 70 amino acids, which is caused by a mutation in the EpoR gene is associated with dominantly inherited human erythrocytosis." Importantly, carboxyl truncations that do not inactivate the receptor nevertheless result in an elimination of receptor protein tyrosine phosphorylation.
In addition to a role for cytokine-induced protein tyrosine phosphorylation, protein tyrosine phosphatases have also been implicated in growth regulation. Initially, protein tyrosine phosphatase inhibitors were observed to stimulate growth of cytokine dependent cell Recent studies have implicated hematopoietic cell phosphatase (HCP; also termed PTP1C/SHP/SHPTPl)22-25 in the negative regulation of hematopoietic growth. HCP contains two SH2 domains at its amino terminus and a carboxyl protein tyrosine phosphatase catalytic domain and is predominantly expressed in hematopoietic cells. Mice genetically deficient in HCP, such as motheaten m i~e ,~~~~' dramatically illustrate the role of HCP in hematopoiesis. These mice die soon after birth because of overproliferation of macrophages and their accumulation in the lungs.28 However, a variety of hematopoietic lineages are expanded. Among the changes is a marked increase in the number of erythroid progenitors, including colony-forming units of the erythroid lineage and erythroid burst-forming cells. 29 The biochemical basis for the essential role that HCP plays in the negative regulation of hematopoiesis is not known. However, recent s t~d i e s~~.~' have shown that HCP associates with c-kit, the receptor for stem cell factor and the p chain of the interleukin-3 (IL-3) receptor after ligand binding. Association requires tyrosine phosphorylation of the receptors and involves the amino terminal SH2 domain of HCP. Overexpression of HCP in IL-3-dependent cells suppresses their ability to proliferate in IL-3, whereas depletion of HCP by antisense expression constructs increases the response to IL-3. Together, the data support the hypothesis that after ligand binding, Jak2 phosphorylation of the receptor creates a bind- ing site for HCP and allows its recruitment into the receptor complex. In the complex, HCP can be hypothesized to dephosphorylate either Jak2 or substrates and thereby negatively influence the response. To further explore the validity of this model, we have examined the ability of HCP to associate with EpoR. The studies show that HCP binds to the phosphorylated form of EpoR and, using in vitro peptide binding assays, we identify potential targets for this binding.
MATERIALS AND METHODS
Cells and reagents. DA-3 and DA-3 cell transfectants of EpoR or EpoR m~t a n t s~.~ were maintained in RPMI-1640 medium supplemented with 10% fetal calf semm (FCS) and recombinant murine IL-3 (30 U/mL). NIH3T3 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FCS. Rabbit polyclonal antisera against the N-terminal peptide of the EpoR or a GST-EpoR fusion protein have been described? Anti-HCP antiserum was developed by immunizing rabbits with the HCP C-terminus peptide." Phosphotyrosine-peptides corresponding to each of the eight tyrosine sites in the cytoplasmic domain of murine E p R were synthesized and prepared following published p r~c e d u r e s .~~
The sequences of these peptides and their positions in EpoR are indicated in Fig 1. All other reagents were purchased from commercial sources unless otherwise noted.
Induction ofprotein tyrosine phosphorylation. Cells were grown in medium supplemented with 0.5% FCS for 16 hours and stimulations were initiated by adding recombinant human Epo. All stimulations were performed at 37°C with recombinant human Epo (30 U/ mL, Amgen, Thousand Oaks, CA).
Immunoprecipitation and Western blotting. lmmunoprecipitation and Western blotting were performed as previously described." Briefly, cells were lysed on ice in cold lysis buffer (50 mmol/L TRIS, pH 7.4; 50 mmollL NaCI; 0.5% sodium deoxycholate; 0.2 mmoln NalVO,; 20 mmoUL NaF 1% NP-40; 2 mmol/L phenylmethylsulfonyl fluoride; 20 pg/mL of aprotinin and 10% glycerol). Cell lysates were clarified by centrifugation for 20 minutes at 10,OOOg at 4°C. Antisera were added to cell lysates and incubated at 4°C for 60 minutes with gentle agitation. Immune complexes were collected with protein A sepharose 4B (Pharmacia, Uppsala, Sweden) at 4°C for 30 minutes, washed gently in cold lysis buffer and analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). For Western blotting, protein samples separated on SDS-PAGE gels were blotted to nitrocellulose membranes (Schleicher & Schuell, Keene, NH). The membranes were then blocked with 5% milk in washing buffer (10 mmoUL TRIS, pH 7.4; 150 mmol/L NaCI; 0.1% Tween-20) for 2 hours, incubated with rabbit polyclonal antibodies (15,000 dilution of whole serum) or with the mouse monoclonal antiphosphotyrosine antibody 4G10 ( I pg/mL; Upstate Biotechnology Inc, Lake Placid, NY) for 2 hours, washed for 1 hour, incubated with secondary antibodies for I hour and washed for another hour. Specific antibody signals were detected using the enhanced chemiluminescence kit (ECL; Amersham, Arlington Heights, IL). Anti-&actin monoclonal antibody (MoAb; Amersham) was also used ( I pg/mL) in Western detection as control for sample loading variations.
GST fusion proteins, phosphopeptide conjugation, and in vitro binding assay. GST fusion proteins of HCP and HCP mutants were prepared as de~cribed.~' GST fusion proteins of KT3 epitope-tagged HCP were generated by mutating the HCP cDNA stop codon TGA to GTC with polymerase chain reaction (PCR) using oligonucleotides (CGG CCA GAG AAC AAG GTC) and then ligating the mutated HCP cDNA to a double-stranded oligonucleotides that encode the KT3 epitope (PPPEPEPT)" plus a C-terminal stop codon. Synthetic tyrosine phosphorylated peptides were conjugated to Affi-gel 10 (Bio-Rad Laboratories, Richmond, CA) following the manufacturer's procedures. For each in vitro binding assay, glutathione beads with =4 pg of bound fusion proteins or 20 pL of peptide conjugated Affi-gel 10 beads (~0 . 2 b g of peptides) were incubated with cell lysates at 4°C for 90 minutes, washed gently two times with cold lysis buffer, boiled off in SDS sample buffer, and analyzed by SDS-PAGE and Western blotting. GST fusion proteins purified from Escherichia coli (1 pg/reaction) or 4G10 MoAb (1 &reaction, UBI) were used in place of cell lysates in some experiments as noted.
Transient transfection and synthetic labeling. NIH3T3 cells were transfected with cDNA clones of wild-type EpoR and an EpoR mutant without the carboxyl terminal 40 amino acids in pXM vector' by calcium phosphate precipitation method. At 72 hours after transfection, the cells were stimulated with Epo and cell lysates were prepared for immunoprecipitation or binding assay as described above. For synthetic labeling, the transfectant cells were washed and incubated for 30 minutes in DMEM medium without L-methionine and L-cysteine (-medium, Bethesda Research Laboratories, Bethesda, MD) and then incubated in -medium supplemented with 10% dialyzed FCS and a mixture of l3'S1 methionine and ["SI cysteine (Tran"S-Labe1, 50 pCi/mL, ICN Pharmaceuticals Inc, Plainview, NY) for 4 hours at 37°C. 34 The labeled EpoR proteins were immunoprecipitated, analyzed by SDS-PAGE, and detected by fluorography. (Fig 3) . The upper band is a nonspecifically reacting band and is seen in unstimulated cells as well as when the fusion protein is run alone (data not shown).
RESULTS

HCP binds EpoR after ligand stimulation through its SH2 domains. DA-3EpoR cells were obtained by transfecting
To further assess the ability of HCP to associate with EpoR, coimmunoprecipitation studies were performed (Fig 4) . Cells were either stimulated with Epo (+) or were untreated (-), extracts prepared and immunoprecipitated with antisera against HCP or EpoR. The proteins were resolved by SDS-PAGE and transferred, and the blots probed with antiserum against HCP. As shown (Fig 4) . HCP coimmunoprecipitated with EpoR after ligand stimulation, but not in unstimulated cells. The potential effects of association on tyrosine phosphorylation and activity of HCP were also examined (Fig 5) . Epo stimulation of Da-3/EpoR cells had no detectable effect on the extent of tyrosine phosphorylation of HCP as assessed by immunoprecipitation and Western blotting with an antiphosphotyrosine MoAb. Nor did Epo stimulation have a detectable effect on the immune complex, in vitro, phosphatase activity of HCP (data not shown).
The arginine residue in the FLVRE motif of SH2 domains is highly conserved and required for binding activity to phosphotyrosine in proteins." To determine whether one or both of the SH2 domains of HCP were involved in binding to EpoR, mutants in which we changed the individual, or both, critical arginine residues were examined (Fig 6) . Mutation of the conserved arginine to a lysine in the first SH2 domain (R K30) abolished binding of the fusion protein to EpoR. Conversely, a comparable mutation in the second SH2 domain (R + K136) had no detectable effect on binding. Lastly, mutation of both residues (K30/136) abolished binding activity. Therefore, the primary EpoR binding site in HCP resides in the first SH2 domain.
The carboxyl terminal region of EpoR is required for receptor phosphorylation and HCP association. To define the region of HCP association and to further establish the role of tyrosine phosphorylation in binding, DA-3 cells expressing various EpoR mutants were examined. The EpoR H mutant was generated by deleting 108 amino acids from the carboxyl domain and retains the ability to support proliferation: although it no longer induces activation of the ras pathway."' As shown in Fig 7, Epo stimulation of cells expressing the EpoR-H mutation results in induction of general tyrosine phosphorylation (TCL), although the receptor is not bound by the HCP SH2 domain fusion protein (SH2) nor is the receptor detectably tyrosine phosphorylated (data not shown). The EpoR-PM4 mutant contains a tryptophane to arginine mutation in the membrane proximal domain, which contains the box-l and box-2 motifs." This mutation results in the inability of the receptor to function mitogenically,h to associate with Jak2,' or to be inducible-tyrosine phosphorylated. As shown in 
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Western: Anti-ptyr Anti-EpoR the above data, HCP did not coimmunoprecipitate with either mutant receptor after Epo binding (data not shown).
We also examined an EpoR mutant containing a carboxyl terminal 40 amino acid deletion which has been previously shown to be hypersensitive to Epo stimulation when expressed in BaF3 cells." In this case, EpoR wild type and the -40 mutant were expressed by transient transfections in NIH3T3 cells (Fig 8) . Both receptors were expressed at comparable levels based on metabolic labeling with "S methionine and immunoprecipitation (Fig SA) . However, after Epo stimulation, only the wild-type receptor was detectably tyrosine phosphorylated (Fig SB, lane 2) . Moreover, only the wild-type receptor was detected under these conditions with the SH2 domain containing GST fusion protein (Fig SB, lane  4) . To determine whether the -40 mutant had any capability of binding to HCP, cell lysates from transfected and Epostimulated cells were mixed with a GST fusion protein containing an epitope-tagged full-length HCP. The extracts were then immunoprecipitated with an antiserum against EpoR and blots probed with an antiserum against the epitope tag. As illustrated (Fig SC) , epitope-tagged HCP coimmunoprecipitated with EpoR from cells transfected with the full-length
EpoR, but not from cells transfected with the -40 mutant.
Together, the data support the conclusion that HCP only recognizes the tyrosine-phosphorylated receptor and that receptor phosphorylation requires the extreme carboxyl region of the cytoplasmic domain. HCP binding to phosphopeptides derived from the cytoplasmic domain of EpoR. Although EpoR can be shown to be tyrosine phosphorylated with antiphosphotyrosine reagents, the low number of functional cell surface receptors has precluded mapping the phosphorylation sites. However, the specificity and affinity of SH2 domains are determined by the amino acids flanking the phosphotyrosine residue and can be assessed by examining the ability of phosphopeptides to bind.32.37 Therefore, we examined the ability of a series of eight peptides, containing the eight tyrosine residues of the EpoR cytoplasmic domain (Fig l) , to bind HCP. For these studies, the phosphopeptides were conjugated to Affigel 10 and assessed for their ability to bind HCP from DA-3 cell extracts (Fig 9) . HCP was bound by the phosphopeptides containing tyrosine residues 427, 455, and 457 (lanes 3 through 5 ) and was weakly bound by a phosphopeptide containing tyrosine residue 367 (Fig 9, lane 2) . In contrast, no binding was detected to peptides containing phosphotyrosine corresponding to residues 469,486,490, or 505. The specificity is indicated by the lack of binding of P-actin to any of the phosphopeptides. All the phosphopeptides were capable of binding a MoAb to phosphotyrosine (Fig 9C) . HCP was not detectably bound by any of the nonphosphorylated peptides under identical conditions (data not shown). Lastly, the ability of the GST-SH2 domain fusion proteins with mutations of the critical arginine residues was examined. Mutation of the second SH2 domain did not alter the phosphopeptide binding activity (Fig 9B) , whereas mutation of the amino terminal SH2, or both SH2 domains, eliminated the ability to bind the phosphopeptides (data not shown).
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were analyzed by SDS-PAGE and by Western blotting with antibody against phosphotyrosine. The binding of HCP to EpoR requires tyrosine phosphorylation. However, because of the low levels of cell surface receptors, it has not been possible to biochemically identify the sites of tyrosine phosphorylation. Based on the lack of detectable tyrosine phosphorylation of receptors that are truncated by 40 amino acids, it might be predicted that phosphorylation occurs at residues 469, 486, 490, or 505. None of the peptides containing these residues were found to bind to the SH2 domain of HCP. However, it is possible that the carboxyl truncations alter the structure of the receptor and affect the ability of an associated kinase to phosphorylate the more membrane proximal sites that are bound by the HCP SH2 domain. Current studies are using point mutations of all the tyrosine residues to identify the in vivo sites of phosphorylation.
The specificity and affinity of SH2 domains is largely determined by the amino acids flanking the phosphotyrosine residues."' Using a phosphopeptide library approach, the amino terminal SH2 domain of HCP showed broad selection for phospho-Tyr-hydrophobic-Xxx-hydrophobic peptides with Phe being slightly preferred at the hydrophobic positions."2 While a Tyr-Phe-Xxx-Phe sequence is not present, four of the cytoplasmic tyrosine residues (367,427,455, and 457), have similar flanking hydrophobic amino acids and, therefore, might have been predicted to be potential HCP binding sites. Consistent with this prediction, peptides containing these residues were bound by the amino SH2 domain of HCP.
In addition to HCP, SHC and the p85 regulatory subunit of PI-3-kinase associate with EpoR through their SH2 do-
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The optimal binding sequences for the SHC SH2 domain, based on screening of phosphopeptide libraries, include sequences that are found flanking tyrosine residues 367 and 455. Therefore, it is possible that SHC and HCP could compete for the same binding sites on the receptor. In contrast, the optimal binding site for the p85 amino terminal SH2 domain was predicted to be phosphotyrosine-MetNal/ Ile/Gl~-Xxx-Met.~' The only tyrosine residue with similarity to this motif is 505 and thus, would not compete for HCP binding if tyrosine phosphorylated.
The sequence specificity for binding of the amino terminal SH2 domain of HCP, determined by screening of phosphopeptide libraries, also includes a site in the J&s.~* The site occurs in the highly conserved sequence (DGYFRL) that is found amino terminal of the kinase-like domain. However, using the approaches describes here, we have been unable to show binding of Epo-induced tyrosine phosphorylated Jak2 to the GST-SH2 domain fusion protein.
Together, the data support the hypothesis that HCP associates with a variety of hematopoietic growth factors through interaction of the amino-terminal SH2 domain of HCP and tyrosine phosphorylated residues in the hematopoietic growth factor receptors. Association with the receptor complexes can be speculated to target the catalytic activity of HCP to proteins within the receptor complex. Although the critical substrates are not known, one of the intriguing possibilities is the autophosphorylation and activation site of the Jaks. Alternatively, or in addition, docking of HCP in the receptor complex might position the phosphatase such that it can dephosphorylate substrates of the Jaks. Irrespective, the recruitment of HCP to the receptor complex competes with the activation signals to negatively affect the response. This may insure that the continual presence of ligand is necessary to sustain a response and drive cells through the initial phase of GI during which ligand is necessary.
